Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSant Uk.8fepf Regulatory News (SANB)

Share Price Information for Sant Uk.8fepf (SANB)

Share Price is delayed by 15 minutes
Get Live Data
142.00    0.00 (0.00%)
Bid:
140.00
Ask:
144.00
Spread: 4.00 (2.857%)
Market Cap: -
SANB Live PriceLast checked at - London Stock Exchange

Intraday Sant Uk.8fepf Share Chart

Admission to Trading

Today 11:27

RNS Number : 3970K
Santander UK Plc
30 June 2026
 

 

SANTANDER UK PLC

(LEI: PTCQB104N23FMNK2RZ28)

NOTES AND CERTIFICATES PROGRAMME

 

NOTIFICATION OF ADMISSION TO TRADING OF TRANSFERABLE SECURITIES

 

The following transferrable securities issued by Santander UK plc (the Issuer) have today 30 June 2026 been admitted to trading on the main market of the London Stock Exchange plc:

 

(1)  Issue of £2,333,099.00 Equity Index Linked Notes due 2031 (the Notes) (XS3305177860).

 

The Notes are issued under the Issuer's Notes and Certificates programme pursuant to a Base Prospectus dated 30 September 2025 (the Base Prospectus) and supplemental prospectuses dated 4 February 2026, 10 March 2026, 1 May 2026 and 5 June, 2026 (the Supplements), read together with the Final Terms dated 16 March 2026.

 

Full information on the Issuer and the offer of the Notes is only available on the basis of the Base Prospectus as supplemented by the Supplements, read together with the applicable Final Terms.

 

The Base Prospectus, the Supplements and the Final Terms have been published on the website of the London Stock Exchange.

 

 

For further information, please contact:

 

Structured Notes Desk

Tel: +44 (0) 20 7756 7000 or structurednotes@santandergbm.com.

 

Please note that the information contained in the Base Prospectus, the Supplement and the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus, the Supplement and/or the Final Terms) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus, the Supplement and/or the Final Terms is not addressed. Prior to relying on the information contained in the Base Prospectus, the Supplement and/or the Final Terms, you must ascertain from the Base Prospectus, the Supplement and/or the Final Terms whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

The Final Terms referenced herein does not constitute an offer of securities for sale in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America, and may not be offered or sold to U.S. persons or to persons within the United States of America, except pursuant to an exemption from the Securities Act.

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ADMBGGDLSDXDGLG
Date   Source Headline
30th Jun 202611:34 amRNSAdmission to Trading
30th Jun 202611:27 amRNSAdmission to Trading
5th Jun 20261:20 pmRNSPublication of a Supplementary Prospectus
5th Jun 20261:15 pmRNSPublication of a Supplementary Prospectus
29th May 20263:49 pmRNSAdmission to trading of Transferable Securities
18th May 20264:01 pmRNSNotice of Redemption
18th May 20263:23 pmRNSAdmission to trading of Transferable Securities
15th May 20262:49 pmRNSPublication of Final Terms
8th May 202610:58 amRNSPublication of a Supplementary Prospectus
1st May 20264:42 pmRNSPublication of a Supplementary Prospectus
1st May 20264:38 pmRNSPublication of a Supplementary Prospectus
1st May 20267:00 amRNSCash Acquisition of TSB Banking Group plc
29th Apr 20267:15 amRNSQuarterly Management Statement - Q1 2026
28th Apr 20264:01 pmRNSAdmission to Trading of Transferable Securities
1st Apr 20263:56 pmRNSPublication of a Prospectus
26th Mar 202611:12 amRNSAdmission to trading of Transferable Securities
25th Mar 20264:30 pmRNSPublication of Final Terms
17th Mar 202612:57 pmRNSPublication of a Prospectus
16th Mar 20264:43 pmRNSNotice of Redemption
10th Mar 20262:08 pmRNSPublication of a Supplementary Prospectus
10th Mar 20262:08 pmRNSPublication of a Supplementary Prospectus
10th Mar 20261:59 pmRNSPublication of a Supplementary Prospectus
10th Mar 20261:59 pmRNSPublication of a Supplementary Prospectus
10th Mar 20267:53 amRNSAnnual Financial Report
10th Mar 20267:53 amRNSAnnual Financial Report
26th Feb 202610:45 amRNSFinal Terms
17th Feb 202612:36 pmRNSPublication of Final Terms
4th Feb 20261:47 pmRNSPublication of a Supplementary Prospectus
4th Feb 20261:42 pmRNSPublication of a Supplementary Prospectus
4th Feb 20267:15 amRNSQuarterly Management Statement – Q4 2025
30th Jan 202610:31 amRNSSantander UK - Chief Executive Officer appointment
13th Jan 20264:29 pmRNSNotice of Redemption
29th Oct 20257:00 amRNSUpdate on Q3 2025 Results
3rd Oct 202511:00 amRNSSantander UK CEO to step down
3rd Oct 20257:00 amRNSSantander UK Board changes
29th Aug 20251:42 pmRNSPublication of Supplementary Prospectus
29th Aug 20251:33 pmRNSPublication of Supplementary Prospectus
29th Aug 20257:30 amRNSHalf-year Report 30 June 2025
30th Jul 20252:10 pmRNSPublication of Suppl.Prospcts
30th Jul 20252:04 pmRNSPublication of Suppl.Prospcts
30th Jul 20257:15 amRNSQuarterly Management Statement Q2 2025
21st May 20252:11 pmRNSPublication of Final Terms
16th May 20254:15 pmRNSChair Appointment
30th Apr 202512:43 pmRNSPublication of Supplementary Prospectus
30th Apr 202512:32 pmRNSPublication of Supplementary Prospectus
30th Apr 20257:15 amRNSQuarterly Management Statement – Q1 2025
4th Apr 20253:04 pmRNSPublication of a Prospectus
2nd Apr 20254:22 pmRNSNotice of Redemption
25th Mar 20259:40 amRNSPublication of Final Terms
25th Mar 20259:36 amRNSPublication of Final Terms

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.